Physician profile

Perry Barrilleaux

Maternal & Fetal Medicine · Lafayette, LA

NPI 1174503569

$229.61

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Maternal & Fetal Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$93.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $60.24 2023-2024
Abbvie INC. $40.65 2021
Daiichi Sankyo INC. $36.82 2021-2022
Evofem Biosciences, INC. $33.05 2022-2024
Pacira Pharmaceuticals Incorporated $15.63 2022
Molnlycke Health Care US, LLC $15.24 2021
Roche Diagnostics Corporation $14.43 2019
Exact Sciences Corporation $13.55 2023 Cologuard Collection Kit

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Perry Barrilleaux

$229.61

in general payments reported 2019-2025

Years
2019-2024
Top company
Bayer Healthcare Pharmaceuticals INC.

https://glasscript.com/doctor/652939/perry-barrilleaux

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.